Please try another search
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Name | Age | Since | Title |
---|---|---|---|
Shai Novik | 55 | 2014 | Executive Chairman |
Abraham Havron | 74 | 2014 | Independent Director |
Roger James Pomerantz | 66 | 2022 | Independent Vice Chairman of the Board |
James L. M. Ferrara | - | - | Clinical Advisor |
Clifford S. Deutschman | - | - | Clinical Advisor |
Mitchell M. Levy | - | - | Clinical Advisor |
Mohamad Mohty | - | - | Clinical Advisor |
Andrew E. Singer | 53 | 2023 | Independent Director |
Paul J. Martin | - | - | Clinical Advisor |
Gili Hart | 49 | 2014 | Independent Director |
Brian Schwartz | 62 | 2020 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review